https://www.selleckchem.com/pr....oducts/crenolanib-cp
The AHR-dependent TGF-α/VEGF-B ratio is altered in a subtype, severity, and disease activity-specific manner and correlates with time to conversion from CIS to MS. It may thus represent a novel marker and serve as additive guideline for immunomodulatory strategies in MS. This study provides Class III evidence that serum levels of AHR, TGF-α, and VEGF-B distinguish subtypes of MS and predict the severity and disease activity of MS. This study provides Class III evidence that serum levels of AHR, TGF-α, and VEGF-B distinguish
Like
Comment
Share
